Investigation and risk assessment by external independent law firm hired by a Special Committee of the Board of Directors found no evidence of wrong doing or inappropriate conduct by Dean Kamen
Sequel Med Tech today announces that an independent and comprehensive investigation and risk assessment conducted by Goodwin Procter LLP, an external law firm engaged by a Special Committee of the Board of Directors, has found no evidence of wrongdoing or inappropriate conduct by Dean Kamen in connection with Jeffrey Epstein or the recently released “Epstein Files.”
Based on its extensive review of all publicly available materials, including those released by the US Department of Justice, plus all documents requested from Dean Kamen’s servers, interviews with relevant parties, and other available evidence, Goodwin Procter concluded that Dean Kamen did not have any meaningful relationship with Jeffrey Epstein and did not engage in, observe, or participate in any inappropriate conduct.
The review identified and confirmed two in-person meetings, both of which were determined to be business-related and aligned with Dean Kamen’s well documented philanthropic efforts. Dean Kamen was persuaded to meet with Epstein on the promise to fund several of Dean’s technologies and foundations and introduce him to potential partners in developing countries. The investigation found that Dean Kamen’s limited interactions with Jeffrey Epstein were solely professional in nature and focused on his long-standing efforts to fund humanitarian and technological initiatives, specifically for water purification and distributed power technologies intended to improve access to clean water and reliable electricity in impoverished regions.
Additionally, the investigation found no evidence that Dean Kamen had knowledge of, observed, or participated in any inappropriate conduct during related travel or meetings, including circumstances involving any underage individuals. The review further determined that individuals who traveled at the request of Mr. Epstein were adults at the time and that there was no evidence of interaction or awareness of misconduct by Dean Kamen.
Throughout this process, Sequel Med Tech has remained focused on its mission to serve people living with diabetes and to deliver innovative products such as the twiist automated insulin delivery system to the community it supports. In light of the investigation’s conclusions, the company will return to normal governance and operations, and Dean Kamen will remain on the Board of Directors and continue his vital role in advancing new life-saving technologies for people with diabetes.
The Special Committee selected Goodwin Procter LLP, and specifically Boston-based Litigation partner Jennifer L. Chunias, to conduct the risk assessment based on its deep experience and recent work with other leading Boston-based academic institutions on similar matters. Ms. Chunias is co-chair of Goodwin’s Private Investment Litigation practice and has more than 20 years of experience conducting internal investigations, risk assessments, and similar reviews. She has led dozens of high-profile internal investigations for private and public companies, educational institutions, boards of directors, and special committees.
